Intel Capital, an investor in the future of compute, has invested in Unisers, a Swiss semiconductor metrology company that identifies invisible contamination-caused defects in semiconductor materials. The USD14 million seed financing round was led
Tags :Vincent Reardon
Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis
Anokion, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. Founded in Switzerland and based
Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio
Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The
Engimmune Therapeutics, a Swiss biotech company based in Basel developing novel T-cell receptor (TCR)-based therapeutics, has closed a CHF 15.5m seed financing round. The round was led by the investors Pureos Bio-ventures and Novo
On February 10, 2022, funds advised by Gilde Buy Out Partners has completed the investment in MBK Fincom, alongside the founders and management which are reinvesting in the business. With this transaction funds advised by Ardian, a
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
Oculis has closed an oversubscribed USD 57m Series C financing round. It was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay
Walder Wyss advises Boehringer Ingelheim. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured left) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital). VISCHER advised
